Hepatic and bile duct cancers

Jingquan Jia, Rachna Shroff

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hepatic and bile duct cancers are one of the deadliest cancers, and their incidence rate and mortality rate are rising in recent years. Hepatocellular carcinoma (HCC) and biliary tract cancers (BTCs) are two different entities with diverse but distinct epidemiological risk factors. Here we reviewed in details of the complex genomic landscape of HCC and BTCs, including main driver mutations, mutational signatures, and integrative molecular classifications. Furthermore, we discussed the clinical applications of genomics for hepatic and bile duct cancers, particularly its impact on prognosis, targeted therapy, and immunotherapy. Major clinical trials of molecularly targeted therapy for HCC and BTCs are reviewed and summarized. Further understanding on the genomics of hepatic and bile duct cancers is crucial in guiding biomarker-directed treatment and advancing personalized treatment.

Original languageEnglish (US)
Title of host publicationGenomic and Precision Medicine
Subtitle of host publicationOncology, Third Edition
PublisherElsevier
Pages217-238
Number of pages22
ISBN (Electronic)9780128006849
ISBN (Print)9780128006535
DOIs
StatePublished - Jan 1 2022
Externally publishedYes

Keywords

  • Hepatocellular carcinoma
  • biliary tract cancers
  • cholangiocarcinoma
  • gallbladder cancer
  • immunotherapy
  • targeted therapy

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Hepatic and bile duct cancers'. Together they form a unique fingerprint.

Cite this